MeiraGTx update after Q3

 

• Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including AAV-AIPL1

• Agreed on pathway with MHRA for Marketing Authorization Application (MAA) under exceptional circumstances for AAV-AIPL1 for the treatment of Leber congenital amaurosis (LCA4) retinal dystrophy without further clinical studies

• Announced positive data from randomized, sham-controlled clinical bridging study of AAV-GAD for the treatment of Parkinson’s disease

https://www.globenewswire.com/news-release/2024/11/13/2980218/0/en/MeiraGTx-Announces-Third-Quarter-2024-Financial-and-Operational-Results-and-Recent-Business-Updates.html